Kura Oncology said its scientific progress is being driven by a people-first, collaborative global culture. The company pointed to new kidney cancer data presen

Kura Oncology said its scientific progress is being driven by a people-first, collaborative global culture. The company pointed to new kidney cancer data presented in Boston and AML research featured on Blood’s cover as signs of continued R&D momentum.